Nonoxidative modifications of lipoproteins in atherogenesis

Annual Review of Nutrition

Volumn 19, Issue , 1999, Pages 123-139

  Tabas, Ira ^a  

^a Columbia University ^*  (United States)

Author keywords

Aggregation; Foam cell; Glycation; Low density lipoprotein; Macrophage

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; FOAM CELL; HUMAN; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; REVIEW;

ANTIGEN-ANTIBODY COMPLEX; ARTERIOSCLEROSIS; CHOLESTEROL; GLYCOSYLATION; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; LIPOSOMES; PROTEOGLYCANS;

EID: 0032810502     PISSN: 01999885     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.nutr.19.1.123     Document Type: Review

References (117)

1. 1. Allen S, Khan S, Al-Mohanna F, Batten P, Yacoub M. 1998. Native low density lipoprotein-induced calcium transients trigger VCAM-I and E-selectin expression in cultured human vascular endothelial cells. J. Clin. Invest. 101:1064-75
2. 2. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, et al. 1996. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Biol. 16: 1074-79
3. 3. Anitschkow N, Chalatow S. 1913. Uber experimentelle cholesterinsteatose und ihre bedeutung fur die entstehung einiger pathologischer prozesse. Zentralhl. Allg. Pathol. 24:1-9
4. 4. Aviram M, Maor I, Keidar S, Hayek T, Oiknine J, et al. 1995. Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Biochem. Biophys. Res. Commun. 216:501-13
5. 5. Ball RY, Stowers EC, Burton JH, Cary NR, Skepper JN, Mitchinson MJ. 1995. Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma. Atherosclerosis 114:45-54
6. 6. Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, et al. 1995. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J. Exp. Med. 182:1959-71
7. 7. Bird DA, Tangirala RK, Fruebis J, Steinberg D, Witztum JL, Palinski W. 1998. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J. Lipid Res. 39:1079-90
8. 8. Boren J, Olin K, Lee I, Chait A, Wight TN, Innerarity TL. 1998. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J. Clin. Invest. 101:2658-64
9. 9. Boren J, Olin K, O'Brien KD, Arnold KS, Ludwig EH, et al. 1998. Engineering non-atherogenic low density lipoproteins: direct evidence for the "Response-to-Retention" hypothesis of atherosclerosis. Circulation. 98:1-314
10. 10. Braunwald E. 1997. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N. Engl. J. Med. 337:1360-69
11. 11. Brown MS, Goldstein JL. 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 52:223-61
12. 12. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, et al. 1994. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. USA 91:9441-45
13. 13. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. 1995. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J. Biol. Chem. 270:10828-32
14. 14. Chao FF, Amende LM, Blanchette-Mackie EJ, Skarlatos SI, Gamble W, et al. 1988. Unesterifjed cholesterol-rich lipid particles in atherosclerotic lesions of human and rabbit aortas. Am. J. Pathol. 131: 73-83
15. 15. Chao FF, Blanchette-Mackie EJ, Tertov VV, Skarlatos SI, Chen YJ, Kruth HS. 1992. Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein to a liposome. J. Biol. Chem. 267:4992-98
16. 16. Chung BH, Tallis G, Yalamoori V, Anantharamaiah GM, Segrest JP. 1994. Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride-rich lipoproteins. Arterioscler. Thromb. 14:622-35
17. 17. Crouse JR III. 1984. Progress in coronary artery disease risk-factor research: What remains to be done? Clin. Chem. 30:1125-27
18. 18. Evans RW, Shaten BJ, Day BW, Kuller LH. 1998. Prospective association between lipid soluble antioxidants and coronary heart disease in men. The Multiple Risk Factor Intervention Trial. Am. J. Epidemiol. 147:180-86
19. 19. Faggioto A, Ross R, Harker L. 1984. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 4:323-40
20. 20. Frank JS, Fogelman AM. 1989. Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching. J. Lipid Res. 30:967-78
21. 21. Fruebis J, Bird DA, Pattison J, Palinski W. 1997. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants. J. Lipid Res. 38:2455-64
22. 22. Gerrity RG. 1991. The role of the monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am. J. Pathol. 103:181-90
23. 23. Gotto AM Jr. 1998. Risk factor modification: rationale for management of dyslipidemia. Am. J. Med. 104:S6-8
24. 24. Greenspan P, Yu H, Mao F, Gutman RL. 1997. Cholesterol deposition in macrophages: foam cell formation mediated by cholesterol-enriched oxidized low density lipoprotein. J. Lipid Res. 38:101-9
25. 25. Guyton JR, Klemp KF. 1996. Development of the lipid-rich core in human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 16:4-11
26. 26. Hendriks WL, van der Sman-de Beer F, van Vlijmen BJ, van Vark LC, Hofker MH, Havekes LM. 1997. Uptake by J774 macrophages of very-low-density lipoproteins isolated from apoE-deficient mice is mediated by a distinct receptor and stimulated by lipoprotein lipase. Arterioscler. Thromb. Biol. 17:498-504
27. 27. Hoff HF, Hoppe G. 1995. Structure of cholesterol-containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation. Curr. Opin. Lipidol. 6:317-25
28. 28. Hoff HF, Morton RE. 1985. Lipoproteins containing apo B extracted from human aortas: structure and function. Ann. NY Acad. Sci. 454:183-94
29. 29. Hoff HF, O'Neil J. 1991. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation. Arterioscler. Thromb. 11:1209-22
30. 30. Hoff HF, O'Neil J, Pepin JM, Cole TB. 1990. Macrophage uptake of cholesterol-containing particles derived from LDL and isolated from atherosclerotic lesions. Eur. Heart J. 11:105-15
31. 31. Hoff HF, Whitaker TE, O'Neil J. 1992. Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition. J. Biol. Chem. 267: 602-9
32. 32. Hoppe G, O'Neil J, Hoff HF. 1994. Inactivation of lysosomal proteases by oxidized low density lipoprotein is partially responsible for its poor degradation by mouse peritoneal macrophages. J. Clin. Invest. 94:1506-12
33. 33. Huang Y, Ghosh MJ, Lopes-Virella MF. 1997. Transcriptional and post-transcriptional regulation of LDL receptor gene expression in PMA-treated THP-I cells by LDL-containing immune complexes. J. Lipid Res. 38:110-20
34. 34. Hurt E, Camejo G. 1987. Effect of arterial proteoglycans on the interaction of LDL with human monocyte-derived macrophages. Atherosclerosis 67:115-26
35. 2 in normal and atherosclerotic arteries. Arterioscler. Thromb. Vasc. Biol. 17:300-9
36. 36. Jerome WG, Lewis JC. 1985. Early atherogenesis in White Carneau pigeons. II. Ultrastructural and cytochemical observations. Am. J. Pathol. 119:210-22
37. 37. Kannel WB, Wilson PW. 1992. Efficacy of lipid profiles in prediction of coronary disease. Am. Heart J. 124:768-74
38. 38. Khoo JC, Miller E, McLoughlin P, Steinberg D. 1988. Enhanced macrophage uptake of low density lipoprotein after self-aggregation. 1988. Arteriosclerosis 8:348-58
39. 39. Khoo JC, Miller E, McLoughlin P, Steinberg D. 1990. Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. J. Lipid Res. 31:645-52
40. 40. Klinkner AM, Waites CR, Kerns WD, Bugelski PJ. 1995. Evidence of foam cell and cholesterol crystal formation in macrophages incubated with oxidized LDL by fluorescence and electron microscopy. J. Histochem. Cytochem. 43: 1071-78
41. 41. Kokkonen JO, Kovanen PT. 1989. Proteolytic enzymes of mast cell granules degrade low density lipoproteins and promote their granule-mediated uptake by macrophages in vitro. J. Biol. Chem. 264: 10749-55
42. 42. Kovanen PT. 1991. Mast cell granule-mediated uptake of low density lipoproteins by macrophages: a novel carrier mechanism leading to the formation of foam cells. Ann. Med. 23:551-59
43. 43. Kovanen PT. 1997. Chymase-containing mast cells in human arterial intima: implications for atherosclerotic disease. Heart Vessels 12(Suppl.):125-27
44. 44. Krieger M, Herz J. 1994. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu. Rev. Biochem. 63:601-37
45. 45. Kruth HS, Skarlatos SI, Gaynor PM, Gamble W. 1994. Production of cholesterol-enriched nascent high density lipoproteins by human monocyte-derived macrophages is a mechanism that contributes to macrophage cholesterol efflux. J. Biol. Chem. 269:24511-18
46. 46. Kruth HS, Skarlatos SI, Lilly K, Chang J, Irim I. 1995. Sequestration of acetylated LDL and cholesterol crystals by human monocyte-derived macrophages. J. Cell Biol. 129:133-45
47. 47. Li F, Hui DY. 1997. Modified low density lipoprotein enhances the secretion of bile salt-stimulated cholesterol esterase by human monocyte-macrophages. Species-specific difference in macrophage cholesteryl ester hydrolase. J. Biol. Chem. 272:28666-71
48. 48. Li F, Hui DY. 1998. Synthesis and secretion of the pancreatic-type carboxyl ester lipase by human endothelial cells. Biochem. J. 329:675-79
49. 49. Libby P, Clinton SK. 1993. The role of macrophages in atherogenesis. Curr. Opin. Lipidol. 4:355-63
50. 50. Lindstedt KA, Kokkonen JO, Kovanen PT. 1992. Soluble heparin proteoglycans released from stimulated mast cells induce uptake of low density lipoproteins by macrophages via scavenger receptor-mediated phagocytosis. J. Lipid Res. 33: 65-75
51. 51. Llorente-Cortes V, Martinez-Gonzalez J, Badimon L. 1998. Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 18:738-46
52. 52. Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G. 1997. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 135:161-70
53. 53. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witztum JL. 1988. Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes 37:550-57
54. 54. Lopes-Virella MF, Virella G. 1992. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes 41(Suppl. 2): 86-91
55. 55. Lopes-Virella MF, Virella G. 1996. Modified lipoproteins, cytokines and macrovascular disease in non-insulin-dependent diabetes mellitus. Ann. Med. 28:347-54
56. 56. Lougheed M, Zhang HF, Steinbrecher UP. 1991. Oxidized low density lipoprotein is resistant to cathepsins and accumulates within macrophages. J. Biol. Chem. 266:14519-25
57. 57. Lyons TJ, Klein RL, Baynes JW, Stevenson HC, Lopes-Virella MF. 1987. Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type 1 (insulin-dependent) diabetic patients: the influence of non-enzymatic glycosylation of low-density lipoproteins. Diabetologia 30:916-23
58. 58. Maher V, Sinfuego J, Chao P, Parekh J. 1997. Primary prevention of coronary heart disease. What has WOSCOPS told us and what questions remain? West Of Scotland Coronary Prevention Study. Drugs 54:1-8
59. 59. Maor I, Mandel H, Aviram M. 1995. Macrophage uptake of oxidized LDL inhibits lysosomal sphingomyelinase, thus causing the accumulation of unesterified cholesterol-sphingomyclin-rich particles in the lysosomes. A possible role for 7-ketocholesterol. Arterioscler. Thromb. Vasc. Biol. 15:1378-87
60. 60. Marathe S, Schissel SL, Yellin MJ, Beatini N, Mintzer R, et al. 1998. Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J. Biol. Chem. 273:4081-88
61. 61. Mora R, Simionescu M, Simionescu N. 1990. Purification and partial characterization of extracellular liposomes isolated from the hyperlipidemic rabbit aorta. J. Lipid Res. 31:1793-807
62. 62. Musanti R, Ghiselli G. 1993. Interaction of oxidized HDLs with J774-A1 macrophages causes intracellular accumulation of unesterified cholesterol. Arterioscler. Thromb. 13:1334-45
63. 63. Myers JN, Tabas I, Jones NL, Maxfield FR. 1993. ?-VLDL is sequestered in surface-connected tubules in mouse peritoneal macrophages. J. Cell Biol. 123: 1389-402
64. 64. Naruszewicz M, Mirkiewicz E, Olszewski AJ, McCully KS. 1994. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutr. Metab. Cardiovasc. Dis. 4:70-77
65. 65. Nievelstein PFEM, Fogelman AM, Mottino G, Frank JS. 1991. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. Arterioscler. Thromb. 11:1795-805
66. 66. Nievelstein-Post P, Mottino G, Fogelman A, Frank J. 1994. An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Arterioscler. Thromb. 14:1151-61
67. 67. Nordestgaard BG, Wootton R, Lewis B. 1995. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler. Thromb. Biol. 15:534-42
68. 68. Olsson AG, Yuan XM. 1996. Antioxidants in the prevention of atherosclerosis. Curr. Opin. Lipidol. 7:374-80
69. 2 only aggregation, of low density lipoprotein particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans. J. Biol. Chem. 273:29127-34
70. 70. Palinski W, Miller E, Witztum JL. 1995. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA 92:821-25
71. 71. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, et al. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA 86:1372-76
72. 72. Pentikainen MO, Lehtonen EMP, Kovanen PT. 1996. Aggregation and fusion of modified low density lipoprotein. J. Lipid Res. 37:2638-49
73. 73. Piha M, Lindstedt L, Kovanen PT. 1995. Fusion of proteolyzed low-density lipoprotein in the fluid phase: a novel mechanism generating atherogenic lipoprotein particles. Biochemistry 34:10120-29
74. 74. Plump AS, Scott CJ, Breslow JL. 1994. Human apolipoprotein A-I gene expression raises HDL and suppresses atherosclerosis in the apo E-deficient mouse. Proc. Natl. Acad. Sci. USA 91:9607-11
75. 75. Rankin SM, de Whalley CV, Hoult JR, Jessup W, Wilkins GM, et al. 1993. The modification of low density lipoprotein by the flavonoids myricetin and gossypetin. Biochem. Pharmacol. 45:67-75
76. 76. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, et al. 1997. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 349: 1715-20
77. 77. Roma P, Catapano AL, Bertulli SM, Varesi L, Fumagalli R, Bernini F. 1990. Oxidized LDL increase free cholesterol and fail to stimulate cholesterol esterification in murine macrophages. Biochem. Biophys. Res. Commun. 171:123-31
78. 78. Ross R. 1995. Cell biology of atherosclerosis. Annu. Rev. Physiol. 57:791-804
79. 79. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. 1991. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353:265-67
80. 80. Ryu BH, Mao FW, Lou P, Gutman RL, Greenspan P. 1995. Cholesteryl ester accumulation in macrophages treated with oxidized low density lipoprotein. Biosci. Biotechnol. Biochem. 59:1619-22
81. 81. Salisbury BG, Falcone DJ, Minick CR. 1985. Insoluble low-density lipoprotein-proteoglycan complexes enhance cholesteryl ester accumulation in macrophages. Am. J. Pathol. 120:6-11
82. 82. Schaffner T, Taylor K, Bartucci E, Fischer-Dzoga K, Beeson J, et al. 1980. Arterial foam cells with distinctive immunomorphologic and histochemical features of macrophages. Am. J. Pathol. 100: 57-73
83. 83. Schissel SL, Jiang XC, Tweedie-Hardman J, Jeong TS, Camejo EH, et al. 1998. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J. Biol. Chem. 273:2738-46
84. 84. Schissel SL, Keesler GA, Schuchman EH, Williams KJ, Tabas I. 1998. The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J. Biol. Chem. 273:18250-59
85. 2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. J. Biol. Chem. 271: 18431-36
86. 86. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. 1996. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J. Clin. Invest. 98:1455-64
87. 87. Seifert PS, Hugo F, Tranum-Jensen J, Zahringer U, Muhly M, Bhakdi S. 1990. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J. Exp. Med. 172:547-57
88. 88. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. 1995. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl. Acad Sci. USA 92:8264-68
89. 89. Steinberg D. 1997. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272:20963-66
90. 90. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. 1989. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:915-24
91. 91. Steinbrecher UP. 1997. Dietary antioxidants and cardioprotection - fact or fallacy? Can. J. Physiol. Pharmacol. 75: 228-33
92. 92. Steinbrecher UP, Lougheed M. 1992. Scavenger receptor-independent stimulation of cholesterol esterification in macrophages by low density lipoprotein extracted from human aortic intima. Arterioscler. Thromb. 12:608-25
93. 93. Steinbrecher UP, Witztum JL. 1984. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 33:130-34
94. 94. Suits AG, Chait A, Aviram M, Heinecke JW. 1989. Phagocytosis of aggregated lipoprotein by macrophages: low density lipoprotein receptor-dependent foam-cell formation. Proc. Natl. Acad. Sci. USA 86:2713-17
95. 95. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, et al. 1997. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386:292-96
96. 96. Szondy E, Lengyel E, Mezey Z, Fust G, Gero S. 1985. Occurrence of anti-low density lipoprotein antibodies and circulating immune complexes in aged subjects. Mech. Age. Dev. 29:117-23
97. 97. Tabas I. 1995. The stimulation of the cholesterol esterification pathway by atherogenic lipoproteins in macrophages. Curr. Opin. Lipidol. 6:260-68
98. 98. Tabas I, Li Y, Brocia RW, Wu SW, Swenson TL, Williams KJ. 1993. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. J. Biol. Chem. 268:20419-32
99. 99. Tertov VV, Sobenin IA, Gabbasov ZA, Popov EG, Orekhov AN. 1989. Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins. Biochem. Biophys. Res. Commun. 163:489-94
100. 100. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, et al. 1998. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler. Thromb. Biol. 18:369-78
101. 101. Tozer EC, Carew TE. 1997. Residence time of low-density lipoprotein in the normal and atherosclerotic rabbit aorta. Circ. Res. 80:208-18
102. 102. Vijayagopal P, Glancy DL. 1996. Macrophages stimulate cholesteryl ester accumulation in cocultured smooth muscle cells incubated with lipoprotein-proteoglycan complex. Arterioscler. Thromb. Biol. 16:1112-21
103. 103. Vijayagopal P, Srinivasan SR, Jones KM, Radhakrishnamurthy B, Berenson GS. 1985. Complexes of low-density lipoproteins and arterial proteoglycan aggregates promote cholesteryl ester accumulation in mouse macrophages. Biochim. Biophys. Acta 837:251-61
104. 104. Virella G, Munoz JF, Galbraith GM, Gissinger C, Chassereau C, Lopes-Virella MF. 1995. Activation of human monocyte-derived macrophages by immune complexes containing low-density lipoprotein. Clin. Immunol. Immunopathol. 75:179-89
105. 105. Vlassara H. 1996. Advanced glycation end-products and atherosclerosis. Ann. Med. 28:419-26
106. 106. Wang X, Bucala R, Milne R. 1998. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proc. Natl. Acad. Sci. USA 95: 7643-47
107. 107. Williams KJ, Tabas I. 1995. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15:551-61
108. 108. Williams KJ, Tabas I. 1998. The response-to-retention hypothesis of atherogenesis, reinforced. Curr. Opin. Lipidol. 9:471-474
109. 109. Witztum JL, Steinbrecher UP, Kesaniemi YA, Fisher M. 1984. Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc. Natl. Acad. Sci. USA 81:3204-8
110. 110. Xu X, Tabas I. 1991. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J. Biol. Chem. 266:24849-58
111. 111. Yancey PG, Jerome WG. 1998. Lysosomal sequestration of free and esterified cholesterol from oxidized low density lipoprotein in macrophages of different species. J. Lipid Res. 39:1349-61
112. 112. Yla-Herttuala S, Jaakkola O, Solakivi T, Kuivaniemi H, Nikkari T. 1986. The effect of proteoglycans, collagen and lysyl oxidase on the metabolism of low density lipoprotein by macrophages. Atherosclerosis 62:73-80
113. 113. Zha XH, Tabas I, Leopold PL, Jones NL, Maxfield FR. 1996. Evidence for prolonged cell-surface contact of acetyl-LDL before entry into macrophages. Arterioscler. Thromb. Vasc. Biol. 90:1421-31
114. 114. Zhang J, Ren S, Sun D, Shen GX. 1998. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18:1140-48
115. 115. Zhang SH, Reddick RL, Avdievich E, Surles LK, Jones RG, et al. 1997. Para7 doxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J. Clin. Invest. 99:2858-66
116. 116. Zhang W, Gaynor PM, Kruth HS. 1997. Aggregated low density lipoprotein induces and enters surface-connected compartments of human monocyte-macrophages. Uptake occurs independently of the low density lipoprotein receptor. J. Biol. Chem. 272:31700-6
117. 117. Zhu Y, Lin JH, Liao HL, Friedli O Jr, Verna L, et al. 1998. LDL induces transcription factor activator protein-1 in human endothelial cells. Arterioscler. Thromb. Biol. 18:473-80